^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MIR9-3 (MicroRNA 9-3)

    i
    Other names: MIR9-3, MicroRNA 9-3, Hsa-MiR-9-5p, Hsa-MiR-9-3p, Hsa-Mir-9-3, MIRN9-3, Hsa-Mir-9-P1_pre, MIMAT0000441, MIMAT0000442, MI0000468, MiRNA9-3, Mir-9-3, RF00237
    Associations

    News

    Trials
    almost2years
    Use of CRISPR/Cas9 with Homology-Directed Repair (HDR) to Gene-Edit Topoisomerase IIβ in Human Leukemia K562 Cells: Generation of a Resistance Phenotype. (PubMed, J Pharmacol Exp Ther)
    Edited clones were partially resistant to mitoxantrone and XK469, while lacking cross-resistance to etoposide and mAMSA. Results demonstrated the import of TOP2ß/180 in drug sensitivity/resistance in K562 cells and revealed differential paralog activity of TOP2-targeted agents.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • MIR9-3 (MicroRNA 9-3)
    |
    etoposide IV • mitoxantrone
    over2years
    Long non-coding RNA MIR22HG inhibits the proliferation and migration, and promotes apoptosis by targeting microRNA-9-3p/ SOCS1 axis in small cell lung cancer cells. (PubMed, Mol Biol Rep)
    In conclusion, MIR22HG in SCLC was found to modulate miR-9-3p level and might act as a possible biomarker for SCLC treatment.
    Journal
    |
    SOCS1 (Suppressor Of Cytokine Signaling 1) • MIR22HG (MIR22 Host Gene) • MIR9-3 (MicroRNA 9-3)
    over2years
    A cuproptosis-related lncRNA signature predicts the prognosis and immune cell status in head and neck squamous cell carcinoma. (PubMed, Front Oncol)
    A novel CRL-related signature has the potential of prognosis prediction in HNSCC. Targeting CRLs may be a promising therapeutic strategy for HNSCC.
    Journal • Immune cell
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • FGF3 (Fibroblast growth factor 3) • TIAM1 (TIAM Rac1 Associated GEF 1) • CDKN2A-DT (CDKN2A Divergent Transcript) • MIR9-3 (MicroRNA 9-3) • TCEA3 (Transcription Elongation Factor A3)
    over2years
    Circular RNA_0000326 accelerates breast cancer development via modulation of the miR-9-3p/YAP1 axis. (PubMed, Neoplasma)
    Furthermore, circ_0000326 silencing prohibited tumor growth of BC in vivo. The research uncovered that circ_0000326 facilitated BC development via mediating the miR-9-3p/YAP1 axis.
    Journal
    |
    YAP1 (Yes associated protein 1) • SOX2 • POU5F1 (POU Class 5 Homeobox 1) • MIR9-3 (MicroRNA 9-3) • TCF4 (Transcription Factor 4)
    over2years
    Stemness-related lncRNAs signature as a biologic prognostic model for head and neck squamous cell carcinoma. (PubMed, Apoptosis)
    The final finding was that these SRlncRNAs were abnormally expressed in HNSCCCS according to the results of RT-qPCR. These 5 SRlncRNAs signature, as a potential prognostic biomarker, can be utilized for personalized medicine in HNSCC patients.
    Journal • IO biomarker
    |
    FOXD2-AS1 (FOXD2 Adjacent Opposite Strand RNA 1) • MIR9-3 (MicroRNA 9-3)
    over3years
    Development and validation of an autophagy-related long non-coding RNA prognostic signature for cervical squamous cell carcinoma and endocervical adenocarcinoma. (PubMed, Front Oncol)
    MIR9-3HG and AC005332.4 belonged to the tumor-suppressor genes and they may play a more positive role in cervical squamous cell carcinoma. This research explored and validated a novel signature of the ARLs, which can be applied to forecast the prognosis of patients with CESC and is closely associated with immune infiltration.
    Journal
    |
    CD8 (cluster of differentiation 8) • MIR9-3 (MicroRNA 9-3) • SMURF2 (SMAD Specific E3 Ubiquitin Protein Ligase 2)
    over3years
    Identification and validation of cuproptosis-related LncRNA signatures as a novel prognostic model for head and neck squamous cell cancer. (PubMed, Cancer Cell Int)
    The 7-CRL signature was presented to be a novel biomarker for predicting prognosis for HNSCC.
    Journal
    |
    MIR9-3 (MicroRNA 9-3)
    |
    cisplatin • dasatinib • gemcitabine • paclitaxel • docetaxel • cytarabine • doxorubicin hydrochloride • etoposide IV • methotrexate
    over3years
    LncRNA MIR9-3HG enhances LIMK1 mRNA and protein levels to contribute to the carcinogenesis of lung squamous cell carcinoma via sponging miR-138-5p and recruiting TAF15. (PubMed, Pathol Res Pract)
    Luciferase reporter, RNA-binding protein immunoprecipitation (RIP), immunofluorescence (IF), fluorescent in situ hybridization (FISH) and RNA pull down assays were implemented to confirm that MIR9-3HG modulates LIM domain kinase 1 (LIMK1) mRNA and protein levels by sequestering microRNA-138-5p (miR-138-5p) and recruiting TATA-box binding protein associated factor 15 (TAF15) protein. Taken together, our research determined that MIR9-3HG up-regulated LIMK1 mRNA and protein levels to promote LUSC carcinogenesis, which offers a novel insight into mechanisms of LUSC.
    Journal
    |
    TAF15 (TATA-Box Binding Protein Associated Factor 15) • MIR138 (MicroRNA 138) • MIR9-3 (MicroRNA 9-3) • TAF1 (TATA-Box Binding Protein Associated Factor 1)
    over3years
    Identification of Prognostic LncRNAs Subtypes Predicts Prognosis and Immune Microenvironment for Glioma. (PubMed, Evid Based Complement Alternat Med)
    Finally, the glioma samples were classified into 2 subgroups based on the median expression of prognosis-related lncRNAs in each sample. In summary, these findings suggest that PRLnc is associated with tumor-infiltrating immune cells in glioma and that subtype 2 patients may respond more positively to immunotherapy.
    Journal • IO biomarker
    |
    MIR9-3 (MicroRNA 9-3)
    |
    miR-155 expression
    over3years
    LncRNA SNHG1 Facilitates Tumor Proliferation and Represses Apoptosis by Regulating PPARγ Ubiquitination in Bladder Cancer. (PubMed, Cancers (Basel))
    the study elucidated that SNHG1 played an important role in bladder cancer and provided a potential therapeutic target for bladder cancer.
    Journal
    |
    PPARG (Peroxisome Proliferator Activated Receptor Gamma) • SNHG1 (Small Nucleolar RNA Host Gene 1) • MIR9-3 (MicroRNA 9-3)